Tags

Type your tag names separated by a space and hit enter

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
J Neural Transm Park Dis Dement Sect. 1995; 10(2-3):91-106.JN

Abstract

The effect of peripheral catechol-O-methyltransferase (COMT) inhibition with entacapone on striatal uptake of 6-[18F]fluoro-L-dopa (FDOPA) was studied with PET both without and with entacapone in fifteen advanced parkinsonian patients and six healthy controls. Entacapone significantly enhanced the fraction of unmetabolized FDOPA in plasma from 16% to about 50% at 80 minutes after FDOPA injection in all subjects. The striatal to occipital ratios and the striatal FDOPA uptake, expressed as a modified decarboxylation coefficient (k3R0), was significantly increased in healthy controls, whereas in parkinsonian patients the increase was significant only in the caudate. On the other hand, the influx constant (Ki) decreased significantly in the caudate and putamen in parkinsonian patients; in healthy controls the Ki remained virtually unchanged. Effective peripheral COMT inhibition markedly increased the fraction of FDOPA in plasma and thus its availability in the brain for decarboxylation both in patients and control subjects. However, the change in striatal FDOPA uptake was modest in the advanced parkinsonian patients as compared to that in control subjects, because of the advanced disease, decreased storage capacity, or both.

Authors+Show Affiliations

Department of Neurology, University of Turku, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9620057

Citation

Ruottinen, H M., et al. "Striatal [18F]fluorodopa Utilization After COMT Inhibition With Entacapone Studied With PET in Advanced Parkinson's Disease." Journal of Neural Transmission. Parkinson's Disease and Dementia Section, vol. 10, no. 2-3, 1995, pp. 91-106.
Ruottinen HM, Rinne JO, Ruotsalainen UH, et al. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91-106.
Ruottinen, H. M., Rinne, J. O., Ruotsalainen, U. H., Bergman, J. R., Oikonen, V. J., Haaparanta, M. T., Solin, O. H., Laihinen, A. O., & Rinne, U. K. (1995). Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. Journal of Neural Transmission. Parkinson's Disease and Dementia Section, 10(2-3), 91-106.
Ruottinen HM, et al. Striatal [18F]fluorodopa Utilization After COMT Inhibition With Entacapone Studied With PET in Advanced Parkinson's Disease. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91-106. PubMed PMID: 9620057.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. AU - Ruottinen,H M, AU - Rinne,J O, AU - Ruotsalainen,U H, AU - Bergman,J R, AU - Oikonen,V J, AU - Haaparanta,M T, AU - Solin,O H, AU - Laihinen,A O, AU - Rinne,U K, PY - 1995/1/1/pubmed PY - 1998/6/10/medline PY - 1995/1/1/entrez SP - 91 EP - 106 JF - Journal of neural transmission. Parkinson's disease and dementia section JO - J Neural Transm Park Dis Dement Sect VL - 10 IS - 2-3 N2 - The effect of peripheral catechol-O-methyltransferase (COMT) inhibition with entacapone on striatal uptake of 6-[18F]fluoro-L-dopa (FDOPA) was studied with PET both without and with entacapone in fifteen advanced parkinsonian patients and six healthy controls. Entacapone significantly enhanced the fraction of unmetabolized FDOPA in plasma from 16% to about 50% at 80 minutes after FDOPA injection in all subjects. The striatal to occipital ratios and the striatal FDOPA uptake, expressed as a modified decarboxylation coefficient (k3R0), was significantly increased in healthy controls, whereas in parkinsonian patients the increase was significant only in the caudate. On the other hand, the influx constant (Ki) decreased significantly in the caudate and putamen in parkinsonian patients; in healthy controls the Ki remained virtually unchanged. Effective peripheral COMT inhibition markedly increased the fraction of FDOPA in plasma and thus its availability in the brain for decarboxylation both in patients and control subjects. However, the change in striatal FDOPA uptake was modest in the advanced parkinsonian patients as compared to that in control subjects, because of the advanced disease, decreased storage capacity, or both. SN - 0936-3076 UR - https://www.unboundmedicine.com/medline/citation/9620057/Striatal_[18F]fluorodopa_utilization_after_COMT_inhibition_with_entacapone_studied_with_PET_in_advanced_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -